Does Long-Term Surveillance Imaging Improve Survival in Patients Treated for Head and Neck Squamous Cell Carcinoma? A Systematic Review of the Current Evidence

References

1. 1.↵
   1. Leeman JE,
   2. Li JG,
   3. Pei X, et al

   . Patterns of treatment failure and postrecurrence outcomes among patients with locally advanced head and neck squamous cell carcinoma after chemoradiotherapy using modern radiation techniques. JAMA Oncol 2017;3:1487–94 doi:10.1001/jamaoncol.2017.0973 pmid:28542679

   CrossRefPubMed
2. 2.↵
   1. Haring CT,
   2. Kana LA,
   3. Dermody SM, et al

   . Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols. Cancer 2023;129:2817–27 doi:10.1002/cncr.34823 pmid:37162461

   CrossRefPubMed
3. 3.↵
   National Comprehensive Cancer Network. Head and Neck Cancers (Version 3.2024). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed April 20, 2024
4. 4.↵
   1. Machiels JP,
   2. Rene Leemans C,
   3. Golusinski W, et al

   ; ESTRO Executive Board. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31:1462–75 doi:10.1016/j.annonc.2020.07.011 pmid:33239190

   CrossRefPubMed
5. 5.↵
   1. Page MJ,
   2. Moher D,
   3. Bossuyt PM, et al

   . PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 2021;372:n160 doi:10.1136/bmj.n160 pmid:33781993

   FREE Full Text
6. 6.↵
   1. Leclere JC,
   2. Clement C,
   3. Le Pennec R, et al

   . An intensive 18F-fludeoxyglucose-positron emission tomography with computed tomography-based strategy of follow-up in patients treated for head and neck squamous cell carcinoma who are clinically asymptomatic. JAMA Netw Open 2023;6:e2326654 doi:10.1001/jamanetworkopen.2023.26654 pmid:37526935

   CrossRefPubMed
7. 7.↵
   1. Canavan JF,
   2. Harr BA,
   3. Bodmann JW, et al

   . Impact of routine surveillance imaging on detecting recurrence in human papillomavirus associated oropharyngeal cancer. Oral Oncol 2020;103:104585 doi:10.1016/j.oraloncology.2020.104585 pmid:32044714

   CrossRefPubMed
8. 8.↵
   1. Chen AM,
   2. Harris JP,
   3. Gan M, et al

   . Posttreatment surveillance imaging after radiation for head and neck cancer. JAMA Netw Open 2023;6:e2342825 doi:10.1001/jamanetworkopen.2023.42825 pmid:37948074

   CrossRefPubMed
9. 9.↵
   1. Ho AS,
   2. Tsao GJ,
   3. Chen FW, et al

   . Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. Cancer 2013;119:1349–56 doi:10.1002/cncr.27892 pmid:23225544

   CrossRefPubMed
10. 10.↵
    1. Anzai Y,
    2. Chang CP,
    3. Rowe K, et al

    . Surveillance imaging with PET/CT and CT and/or MRI for head and neck cancer and mortality: a population-based study. Radiology 2023;307:e212915 doi:10.1148/radiol.212915 pmid:36625743

    CrossRefPubMed
11. 11.↵
    1. Sterne JA,
    2. Hernan MA,
    3. Reeves BC, et al

    . ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919 doi:10.1136/bmj.i4919 pmid:27733354

    FREE Full Text
12. 12.↵
    1. Beswick DM,
    2. Gooding WE,
    3. Johnson JT, et al

    . Temporal patterns of head and neck squamous cell carcinoma recurrence with positron-emission tomography/computed tomography monitoring. Laryngoscope 2012;122:1512–17 doi:10.1002/lary.23341 pmid:22685038

    CrossRefPubMed
13. 13.↵
    1. Imbimbo M,
    2. Alfieri S,
    3. Botta L, et al

    . Surveillance of patients with head and neck cancer with an intensive clinical and radiologic follow-up. Otolaryngol Head Neck Surg 2019;161:635–42 doi:10.1177/0194599819860808 pmid:31286827

    CrossRefPubMed
14. 14.↵
    1. Ng SP,
    2. Pollard C 3rd.,
    3. Berends J, et al

    . Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. Cancer 2019;125:1823–29 doi:10.1002/cncr.31983 pmid:30748005

    CrossRefPubMed
15. 15.↵
    1. Kostakoglu L,
    2. Fardanesh R,
    3. Posner M, et al

    . Early detection of recurrent disease by FDG-PET/CT leads to management changes in patients with squamous cell cancer of the head and neck. Oncologist 2013;18:1108–17 doi:10.1634/theoncologist.2013-0068 pmid:24037978

    Abstract/FREE Full Text
16. 16.↵
    1. Ng SP,
    2. Pollard C 3rd.,
    3. Kamal M, et al

    . Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. NPJ Precis Oncol 2019;3:22 doi:10.1038/s41698-019-0097-y pmid:31583278

    CrossRefPubMed
17. 17.↵
    1. Homer JJ,
    2. Winter SC,
    3. Abbey EC, et al

    . Head and Neck Cancer: United Kingdom National Multidisciplinary Guidelines, Sixth Edition. J Laryngol Otol 2024;138:S1–224 doi:10.1017/S0022215123001615 pmid:38482835

    CrossRefPubMed
18. 18.↵
    1. Aiken AH,
    2. Rath TJ,
    3. Anzai Y, et al

    . ACR Neck Imaging Reporting and Data Systems (NI-RADS): a white paper of the ACR NI-RADS Committee. J Am Coll Radiology 2018;15:1097–108 doi:10.1016/j.jacr.2018.05.006 pmid:29983244

    CrossRefPubMed
19. 19.↵
    1. Van Hoe S,
    2. Hermans R

    . Post-treatment surveillance imaging in head and neck cancer: a systematic review. Insights Imaging 2024;15:32 doi:10.1186/s13244-023-01578-4 pmid:38315325

    CrossRefPubMed
20. 20.↵
    1. Rangaswamy B,
    2. Fardanesh MR,
    3. Genden EM, et al

    . Improvement in the detection of locoregional recurrence in head and neck malignancies: F-18 fluorodeoxyglucose-positron emission tomography/computed tomography compared to high-resolution contrast-enhanced computed tomography and endoscopic examination. Laryngoscope 2013;123:2664–69 doi:10.1002/lary.24077 pmid:23553147

    CrossRefPubMed
21. 21.↵
    1. Breik O,
    2. Kumar A,
    3. Birchall J, et al

    . Follow up imaging of oral, oropharyngeal and hypopharyngeal cancer patients: comparison of PET-CT and MRI post treatment. J Craniomaxillofac Surg 2020;48:672–79 doi:10.1016/j.jcms.2020.04.008 pmid:32513432

    CrossRefPubMed
22. 22.↵
    1. Hartl DM,
    2. Guerlain J,
    3. Gorphe P, et al

    . Review of outcomes after salvage surgery for recurrent squamous cell carcinoma of the head and neck. Cancers (Basel) 2023;15:15 doi:10.3390/cancers15194692 pmid:37835386

    CrossRefPubMed
23. 23.↵
    1. Cohen EE,
    2. Soulieres D,
    3. Le Tourneau C, et al

    ; KEYNOTE-040 Investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019;393:156–67 doi:10.1016/S0140-6736(18)31999-8 pmid:30509740

    CrossRefPubMed
24. 24.↵
    1. Huang SH,
    2. Perez-Ordonez B,
    3. Weinreb I, et al

    . Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol 2013;49:79–85 doi:10.1016/j.oraloncology.2012.07.015 pmid:22917550

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Fakhry C,
    2. Zhang Q,
    3. Nguyen-Tan PF, et al

    . Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol 2014;32:3365–73 doi:10.1200/JCO.2014.55.1937 pmid:24958820

    Abstract/FREE Full Text
26. 26.↵
    1. Sinha P,
    2. Thorstad WT,
    3. Nussenbaum B, et al

    . Distant metastasis in p16-positive oropharyngeal squamous cell carcinoma: a critical analysis of patterns and outcomes. Oral Oncol 2014;50:45–51 doi:10.1016/j.oraloncology.2013.10.007 pmid:24211084

    CrossRefPubMed
27. 27.↵
    1. Trosman SJ,
    2. Koyfman SA,
    3. Ward MC, et al

    . Effect of human papillomavirus on patterns of distant metastatic failure in oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. JAMA Otolaryngol Head Neck Surg 2015;141:457–62 doi:10.1001/jamaoto.2015.136 pmid:25742025

    CrossRefPubMed
28. 28.↵
    1. Gore A,
    2. Baugnon K,
    3. Beitler J, et al

    . Posttreatment imaging in patients with head and neck cancer without clinical evidence of recurrence: should surveillance imaging extend beyond 6 months? AJNR Am J Neuroradiol 2020;41:1238–44 doi:10.3174/ajnr.A6614 pmid:32554418

    Abstract/FREE Full Text
29. 29.↵
    PET-CT guided, symptom-based, patient-initiated surveillance versus clinical follow-up in advanced head neck cancer (PET NECK 2). Trial number: NIHR200861. https://www.petneck2.com/randomised-controlled-trial/. Accessed June 9, 2024
30. 30.↵
    Gustave Roussy Cancer Campus. Multicentric comparative study between a conventional and an intensive follow up strategy after treatment of a head and neck squamous cell carcinoma (SURVEILL’ORL). https://clinicaltrials.gov/study/NCT03519048. Accessed May 14, 2024
31. 31.↵
    Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori of Milan. Health and Economic Outcomes of Two Different Follow up Strategies in Effectively Cured Advanced Head and Neck Cancer (HETeCo). https://clinicaltrials.gov/study/NCT02262221. Accessed May 24, 2024
32. 32.↵
    University of Pittsburgh. Phase III Trial of PET/CT vs. CT Surveillance for Head and Neck Cancer. https://www.clinicaltrials.gov/study/NCT02655068. Accessed May 24, 2024
33. 33.↵
    1. Roman BR,
    2. Lohia S,
    3. Mitra N, et al

    . Perceived value drives use of routine asymptomatic surveillance PET/CT by physicians who treat head and neck cancer. Head Neck 2020;42:974–87 doi:10.1002/hed.26071 pmid:31919944

    CrossRefPubMed
34. 34.↵
    1. McLaren O,
    2. Perkins C,
    3. Zhu Y, et al

    . Patient perspectives on surveillance after head and neck cancer treatment: a systematic review. Clin Otolaryngol 2021;46:1345–53 doi:10.1111/coa.13846 pmid:34363645

    CrossRefPubMed
35. 35.↵
    1. Hsu D,
    2. Rath TJ,
    3. Branstetter BF, et al

    . Interrater reliability of NI-RADS on posttreatment PET/contrast-enhanced CT scans in head and neck squamous cell carcinoma. Radiol Imaging Cancer 2021;3:e200131 doi:10.1148/rycan.2021200131 pmid:34018845

    CrossRefPubMed
36. 36.↵
    1. Baba A,
    2. Kurokawa R,
    3. Kurokawa M, et al

    . Performance of NECK IMAGING REPORTING and DATA SYSTEM (NI-RADS) for diagnosis of recurrence of head and neck squamous cell carcinoma: a systematic review and meta-analysis. AJNR Am J Neuroradiol 2023;44:1184–90 doi:10.3174/ajnr.A7992 pmid:37709352

    Abstract/FREE Full Text
37. 37.↵
    1. Ng SP,
    2. Ajayi T,
    3. Schaefer AJ, et al

    . Surveillance imaging for patients with head and neck cancer treated with definitive radiotherapy: a partially observed Markov decision process model. Cancer 2020;126:749–56 doi:10.1002/cncr.32597 pmid:31725906

    CrossRefPubMed
38. 38.↵
    1. Lee HI,
    2. Lee J,
    3. Lee JH, et al

    . Evaluation of optimal assessment schedules for surveillance after definitive locoregional treatment of locally advanced head and neck cancer: a retrospective cohort study with parametric modeling of event-free survival. JAMA Otolaryngol Head Neck Surg 2022;148:1059–67 doi:10.1001/jamaoto.2022.2561 pmid:36173618

    CrossRefPubMed
39. 39.↵
    1. Berger BM,
    2. Hanna GJ,
    3. Posner MR, et al

    . Detection of occult recurrence using circulating tumor tissue modified viral HPV DNA among patients treated for HPV-driven oropharyngeal carcinoma. Clin Cancer Res 2022;28:4292–301 doi:10.1158/1078-0432.CCR-22-0562 pmid:35576437

    CrossRefPubMed
40. 40.↵
    1. Flach S,
    2. Howarth K,
    3. Hackinger S, et al

    . Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS): a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma. Br J Cancer 2022;126:1186–95 doi:10.1038/s41416-022-01716-7 pmid:35132238

    CrossRefPubMed
41. 41.↵
    1. Lele SJ,
    2. Adilbay D,
    3. Lewis E, et al

    . ctDNA as an adjunct to posttreatment PET for head and neck cancer recurrence risk assessment. Otolaryngol Head Neck Surg 2024;171:439–44 doi:10.1002/ohn.760 pmid:38591659

    CrossRefPubMed